Small molecules that allosterically inhibit p21-activated kinase activity by binding to the regulatory p21-binding
Duk-Joong Kim1, Chang-Ki Choi2, Chan-Soo Lee3
1Research Institute and Quality Management Team, NanoPharm Corp., Jincheon-gun, Korea.
Abstract:
p21-activated kinases (PAKs) are key regulators of actin dynamics, cell proliferation and cell survival. Deregulation of PAK activity contributes to the pathogenesis of various human diseases, including cancer and neurological disorders. Using an ELISA-based screening protocol, we identified naphtho(hydro)quinone-based small molecules that allosterically inhibit PAK activity. These molecules interfere with the interactions between the p21-binding domain (PBD) of PAK1 and Rho GTPases by binding to the PBD. Importantly, they inhibit the activity of full-length PAKs and are selective for PAK1 and PAK3 in vitro and in living cells. These compounds may potentially be useful for determining the details of the PAK signaling pathway and may also be used as lead molecules in the development of more selective and potent PAK inhibitors.
Related Concept Videos
The JAK-STAT Signaling Pathway
Inhibition of Cdk Activity
Inhibition of CDK Activity
Allosteric Regulation
Allosteric Regulation
PI3K/mTOR/AKT Signaling Pathway


